Q2 2025 Earnings Forecast for McKesson Co. (NYSE:MCK) Issued By Leerink Partnrs

McKesson Co. (NYSE:MCK) – Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of McKesson in a research note issued to investors on Sunday, August 18th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $7.32 for the quarter, down from their prior estimate of $7.78. The consensus estimate for McKesson’s current full-year earnings is $31.68 per share. Leerink Partnrs also issued estimates for McKesson’s FY2025 earnings at $32.25 EPS and FY2026 earnings at $36.03 EPS.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, August 7th. The company reported $7.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.21 by $0.67. McKesson had a net margin of 0.97% and a negative return on equity of 245.88%. The business had revenue of $79.28 billion for the quarter, compared to the consensus estimate of $82.53 billion. During the same period in the previous year, the firm earned $7.27 EPS. The business’s revenue was up 6.4% on a year-over-year basis.

MCK has been the topic of a number of other reports. Barclays boosted their price target on shares of McKesson from $596.00 to $616.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Evercore ISI decreased their price target on shares of McKesson from $660.00 to $630.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Robert W. Baird cut their price objective on McKesson from $694.00 to $671.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Wells Fargo & Company boosted their target price on McKesson from $502.00 to $551.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 9th. Finally, Bank of America increased their price target on McKesson from $590.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Two investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $609.79.

McKesson Trading Up 0.0 %

Shares of NYSE MCK opened at $548.52 on Wednesday. The stock has a fifty day simple moving average of $586.71 and a 200-day simple moving average of $553.79. McKesson has a twelve month low of $404.72 and a twelve month high of $637.51. The stock has a market capitalization of $71.27 billion, a PE ratio of 24.51, a PEG ratio of 1.46 and a beta of 0.45.

McKesson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 1st. Shareholders of record on Monday, September 2nd will be paid a $0.71 dividend. The ex-dividend date of this dividend is Friday, August 30th. This is a positive change from McKesson’s previous quarterly dividend of $0.62. This represents a $2.84 dividend on an annualized basis and a yield of 0.52%. McKesson’s payout ratio is currently 12.69%.

Insider Activity

In related news, CFO Britt J. Vitalone sold 12,752 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $558.09, for a total transaction of $7,116,763.68. Following the transaction, the chief financial officer now owns 14,028 shares of the company’s stock, valued at $7,828,886.52. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other McKesson news, CFO Britt J. Vitalone sold 12,752 shares of McKesson stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $558.09, for a total value of $7,116,763.68. Following the transaction, the chief financial officer now directly owns 14,028 shares in the company, valued at approximately $7,828,886.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Brian S. Tyler sold 3,753 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $626.03, for a total value of $2,349,490.59. Following the sale, the chief executive officer now directly owns 82,339 shares of the company’s stock, valued at $51,546,684.17. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,713 shares of company stock valued at $18,702,605. Insiders own 0.11% of the company’s stock.

Institutional Investors Weigh In On McKesson

A number of hedge funds have recently added to or reduced their stakes in the company. Intrust Bank NA purchased a new stake in shares of McKesson in the fourth quarter valued at approximately $206,000. Heritage Wealth Management LLC acquired a new stake in shares of McKesson in the fourth quarter valued at about $1,538,000. Councilmark Asset Management LLC acquired a new position in McKesson during the first quarter worth about $5,160,000. Atlantic Edge Private Wealth Management LLC acquired a new stake in shares of McKesson during the 4th quarter valued at approximately $2,487,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of McKesson by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 804,338 shares of the company’s stock worth $372,393,000 after acquiring an additional 10,977 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.